Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea

Genton, Blaise; Al-Yaman, Fadwa; Anders, Robin F.; Saul, Allan; Brown, Graham V.; Pye, David; Irving, David O.; Briggs, William R.S; Mai, A.; Ginny, Meza; Adiguma, Thomas; Rare, Lawrence; Giddy, Andrew; Reber-Liske, Rosemaria; Stuerchler, Dieter; Alpers, Michael P.

doi:10.1016/s0264-410x(00)00036-0

Cited by 96 publications

(59 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To make this study as relevant as possible, wellcharacterized clinical grade protein was used as the immunogen, and an adjuvant (Montanide ISA-720) was selected that is currently being used in a number of human vaccine trials. 21,22 An important finding is that antibodies to Pvs25 were rapidly produced in Aotus monkeys after the first vaccination with Pvs25 and were still detectable in these animals for 180 days after the last booster immunization. When plasma from the immunized animals was tested for its capacity to block parasite transmission in a mosquito artificial MFA, plasma showed complete blocking of transmission in all assays, establishing the functionality of the elicited immune response.…”

Section: Discussionmentioning

confidence: 99%

Induction of Transmission-Blocking Immunity in Aotus Monkeys by Vaccination With a Plasmodium Vivax Clinical Grade Pvs25 Recombinant Protein

Arévalo‐Herrera

Solarte

Yasnot

et al. 2005

The American Journal of Tropical Medicine and Hygiene

Self Cite

View full text Add to dashboard Cite

Abstract. Aotus monkeys were used to determine the immunogenicity of Pvs25 protein expressed in the zygote/ ookinete surface. Animals were immunized in three times with 100 g of Pvs25 formulated in Montanide ISA-720. Antibodies to Pvs25 detected by an enzyme-linked immunosorbent assay appeared by day 30 after the first immunization, with a peak of antibodies levels on day 150. These antibodies were still detectable on day 300. Plasma samples on day 150 from experimental group were able to completely block the development of the parasite in Anopheles albimanus mosquitoes artificially fed with human isolates of Plasmodium vivax. Immunized Aotus monkeys were infected with blood forms of the P. vivax Salvador I strain and no boosting effect of blood infection on titers of antibodies to Pvs25 was observed despite the presence of infective gametocytes. In conclusion, Pvs25 protein formulated in Montanide ISA-720 induces efficient and long-lasting transmission-blocking antibodies that cannot be boosted by parasite infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Induction of Transmission-Blocking Immunity in Aotus Monkeys by Vaccination With a Plasmodium Vivax Clinical Grade Pvs25 Recombinant Protein

Arévalo‐Herrera

Solarte

Yasnot

et al. 2005

The American Journal of Tropical Medicine and Hygiene

Self Cite

View full text Add to dashboard Cite

show abstract

“…Malaria CS synthetic peptide vaccines or recombinant blood stage vaccines adjuvanted with Montanide ISA 720 have shown promising results in nonhuman primates and phase I clinical studies (1,7,14,20,40). Immunization protocols in which primary doses with vaccine formulated in Montanide ISA 720 are followed with a booster inoculation containing the same antigen in a different adjuvant have reduced reactogenicity noted with some antigenMontanide ISA 720 formulations (39,49).…”

Section: Discussionmentioning

confidence: 99%

A Modified Hepatitis B Virus Core Particle Containing Multiple Epitopes of thePlasmodium falciparumCircumsporozoite Protein Provides a Highly Immunogenic Malaria Vaccine in Preclinical Analyses in Rodent and Primate Hosts

Birkett¹,

Lyons²,

Schmidt³

et al. 2002

Infect Immun

View full text Add to dashboard Cite

“…16 Pf190L was shown to be the most immunogenic molecule in that vaccine cocktail and is likely to be responsible for part of the protection induced. 17 Here we report the results of studies conducted with a P. vivax MSP-1 protein fragment termed Pv200L because of its sequence homology to Pf190L. This protein fragment was expressed as a recombinant protein in Escherichia coli (rPv200L) and tested for its antigenicity and vaccine potential both in BALB/c mice and Aotus monkeys.…”

Section: Introductionmentioning

confidence: 99%

Antigenicity, Immunogenicity, and Protective Efficacy of Plasmodium Vivax Msp1 Pv200l: A Potential Malaria Vaccine Subunit

Valderrama-Aguirre

Quintero

Gomez

et al. 2005

The American Journal of Tropical Medicine and Hygiene

117

View full text Add to dashboard Cite

Abstract. The merozoite surface protein 1 (MSP-1) is expressed in all Plasmodium species and is considered a major malaria vaccine candidate. We found that MSP-1 from Plasmodium vivax (PvMSP-1) contains a region of significant sequence homology with the 190L subunit vaccine derived from the P. falciparum MSP-1. The fragment, termed Pv200L, was expressed as a recombinant protein in Escherichia coli (rPv200L) and used to asses its immunologic relevance as a vaccine target. A cross-sectional, seroepidemiologic study conducted in Buenaventura, Colombia showed that 52.2% (95% confidence interval [CI] ‫ס‬ 39.8-64.3) of individuals previously exposed to P. vivax and 72.8% (95% CI ‫ס‬ 61.8-82.1) of P. vivax-infected patients had IgG antibodies to rPv200L. Immunization of BALB/c mice and Aotus monkeys induced IgG antibodies (titer > 10 6 ) that cross-reacted with P. vivax parasites. Immunized monkeys displayed partial protection against a challenge with P. vivax blood stages. Our results suggest that Pv200L is a new malaria vaccine subunit and deserves further testing.

show abstract

Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea

Cited by 96 publications

References 26 publications

Induction of Transmission-Blocking Immunity in Aotus Monkeys by Vaccination With a Plasmodium Vivax Clinical Grade Pvs25 Recombinant Protein

Induction of Transmission-Blocking Immunity in Aotus Monkeys by Vaccination With a Plasmodium Vivax Clinical Grade Pvs25 Recombinant Protein

A Modified Hepatitis B Virus Core Particle Containing Multiple Epitopes of thePlasmodium falciparumCircumsporozoite Protein Provides a Highly Immunogenic Malaria Vaccine in Preclinical Analyses in Rodent and Primate Hosts

Antigenicity, Immunogenicity, and Protective Efficacy of Plasmodium Vivax Msp1 Pv200l: A Potential Malaria Vaccine Subunit

Contact Info

Product

Resources

About